Earnings Call · Q4 FY2024·2025-03-03

Q4 24EPS +15.91%·Rev n/aQ3 24EPS -18.42%·Rev n/aQ2 24EPS -2.78%·Rev n/aQ1 24EPS -6.25%·Rev n/a⚠ consensus missing

Neumora Therapeutics, Inc. NMRA

Helen Rubinstein — Vice President of Investor Relations and Communications

Paul Berns — Chief Executive Officer (CEO)

Josh Pinto — President

Bill Aurora — Unspecified - likely senior management or clinical development based on context

Michael Milligan — Unspecified - likely Chief Financial Officer or similar based on financial results discussion

−9.9%1d on move date−8.2% vs SPY3d−8.3%5d−4.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NMRA calls or request research access.

More NMRA calls Browse calls Request research access